Overview
Left atrial enlargement (LAE) is an unusual increase in left atrial size (volume) that contributes to cardiovascular disease. This article explains how LAE differs based on biological sex and its clinical implications.2,3,11
Causes of left atrial enlargement
LAE develops when the left atrium is chronically exposed to increased pressure and when it undergoes remodelling due to structural disease. Common factors include:
- Hypertension
- Heart failure with preserved ejection fraction (HFpEF)
- Atrial fibrillation (AF) (both cause and consequence)
- Congenital or acquired cardiomyopathies
Endurance training may cause a benign, symmetric atrial enlargement in some athletes. Fibrosis and atrial myopathy also remodel atrial structure and size.2,8,9
Symptoms
LAE is often asymptomatic. However, typical clinical features include:5,10
- Shortness of breath
- Irregular heartbeat (from AF)
- Reduced exercise capacity
- Neurological deficits may occur due to thromboembolism ( a blood clot dislodges from its original site and travels elsewhere, causing obstruction to the blood flow)
Many patients are diagnosed coincidentally during echocardiography performed for AF, stroke or heart failure assessment.2,8
Associated risks
An abnormally large LA correlates with a higher chance of AF and enhanced cardiovascular diseases. Its size correlates with the degree of atrial remodelling and fibrosis. Larger LA volume is also linked to higher recurrence of AF.11,12 Modern society guidelines recommend using LA volume as a significant biomarker when assessing stroke risk, rhythm and timing of intervention for valvular disease.14,15
Diagnosis
There are multiple ways to diagnose enlargement of the LA. Echocardiography uses ultrasound to measure the volume of the LA. It is reported as left atrial volume indexed to body surface area (LAVI, mL/m²). Modern guidelines recommend LAVI as the most reproducible and reliable measure, as it provides sex and body size-adjusted normal limits (normal LAVI ≈ 16 to 34 mL/m²).
Also used is cardiac MRI, which provides accurate volumetrics and tissue characterisation. It can identify further risk factors such as AF from LA scarring, which can imply LA enlargement.3,4,6
Treatment
No treatment shrinks the LA. However, management of lifestyle factors such as diet and exercise targets underlying causes and helps to decrease LA volume or reverse remodelling where possible:11,13
- Controlling lifestyle factors is the most effective way to decrease blood pressure, for example, by eating a balanced diet, while incorporating regular exercise and limiting caffeine and alcohol intake
- Restoring sinus rhythm with antiarrhythmic drugs can reduce LA size over time in some patients
- Anticoagulation decisions are based on stroke risk rather than LA size alone. LAE typically coexists with other risk factors that increase the stroke score, and some procedural strategies have sex-specific outcome considerations
Overall, an integrated, patient-centred approach is needed, and procedural therapies should be used with attention to individual risk and LA structural state rather than being based on generalisation.1,11
Differences in left atrial enlargement in males and females
Men generally have larger LA dimensions due to a larger body size. Using indexed volumes is essential to avoid under- or overdiagnosis between sexes.3,6,16
- Typically, AF incidence has been higher in men, but women with comparable risk factor profiles often have smaller atria yet a higher risk of stroke and death once AF develops. Recent analyses imply that after controlling for body size and cardiovascular disease, women may have a similar or even higher risk of developing AF and worse outcomes7,15
- Imaging studies suggest women may present with more advanced fibrotic remodelling relative to LA size, and this can reduce the success rates of rhythm-control interventions, if rhythm is disrupted and instead increase AF recurrence. On the other hand, men may more often have LA enlargement driven by volume overload or structural disease13
- Women who exhibit LA disease and/or AF are often older. Some studies show higher complication rates in women, and they display more symptoms13,14
- Due to different symptoms among males and females, the debate of tailoring therapies based on sex is ongoing. Current major guidelines stress that individualised care should be prioritised more than considering the general consensus, but still recognise sex as an important modifier of risk and outcome9,11
FAQs
Can LA size decrease with diet management?
Yes. Treating the underlying factor, e.g. hypertension from obesity, by eating a balanced diet, can reduce LA pressure and, in some patients, reduce LA volume over months. It is recommended to also participate in regular exercise 4-5 times per week, as when the heart is exercised, more blood can be pumped to organs faster, and several bodily functions can occur more efficiently.11,14
Are women underdiagnosed because of smaller hearts?
Yes. If diameters are used without indexing, women can be misclassified. Indexed measurements reduce misdiagnosis. Clinicians should interpret LA measures in the context of body size and symptoms.3,6
Does LAE predict the need for valve surgery?
Yes, especially when there is an increased presence of symptoms. In valvular disease, progressive LAE indicates chronic volume overload and helps to guide timing for intervention alongside symptoms and poor ventricular function. Evidence links LAE to worse outcomes if intervention is delayed.15
Summary
Left atrial enlargement is a common, clinically significant marker of cardiovascular disease and future risk, especially for AF, stroke and heart-failure progression. Diagnosis relies on modern echocardiographic volumetrics (indexed LA volume) and, where needed, MRI.
Modifying lifestyle choices mostly targets underlying causes and symptom control. Sex modifies both LA size and clinical consequence, where men have larger atria but women may experience worse outcomes and show different remodelling patterns. Awareness of these sex differences and use of indexed, guideline-recommended measures improves diagnosis, risk stratification and personalised management.
References
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging [Internet]. 2015 [cited 2026 Feb 2]; 16(3):233–71. Available from: https://academic.oup.com/ehjcimaging/article-lookup/doi/10.1093/ehjci/jev014.
- Parajuli P, Alahmadi MH, Ahmed AA. Left Atrial Enlargement. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Feb 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK553096/.
- Jumani AI, Mani SC, Rashwan GA, Ibrahim HO, Aldhaheri JS, Almohdar SM, et al. The case for indexing. Saudi Med J [Internet]. 2025 [cited 2026 Feb 2]; 46(7):746–50. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12251580/.
- Harkness A, Ring L, Augustine DX, Oxborough D, Robinson S, Sharma V. Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography. Echo Res Pract [Internet]. 2020 [cited 2026 Feb 2]; 7(1):G1–18. Available from: https://echo.biomedcentral.com/articles/10.1530/ERP-19-0050.
- Hoit BD. Left Atrial Size and Function. Journal of the American College of Cardiology [Internet]. 2014 [cited 2026 Feb 2]; 63(6):493–505. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109713060816.
- Siddiqi HK, Vinayagamoorthy M, Gencer B, Ng C, Pester J, Cook NR, et al. Sex Differences in Atrial Fibrillation Risk. JAMA Cardiol [Internet]. 2022 [cited 2026 Feb 2]; 7(10):1027–35. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434484/.
- Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le Tourneau T, et al. Prognostic Implications of Left Atrial Enlargement in Degenerative Mitral Regurgitation. Journal of the American College of Cardiology [Internet]. 2019 [cited 2026 Feb 2]; 74(7):858–70. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109719356888.
- Agrawal V, Manouchehri A, Vaitinadin NS, Shi M, Bagheri M, Gupta DK, et al. Identification of Clinical Drivers of Left Atrial Enlargement through Genomics of Left Atrial Size. Circ Heart Fail [Internet]. 2024 [cited 2026 Feb 2]; 17(1):e010557. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10842187/.
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal [Internet]. 2021 [cited 2026 Feb 2]; 42(5):373–498. Available from: https://academic.oup.com/eurheartj/article/42/5/373/5899003.
- Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal [Internet]. 2024 [cited 2026 Feb 2]; 45(36):3314–414. Available from: https://academic.oup.com/eurheartj/article/45/36/3314/7738779.
- De Caterina AR, Nielsen-Kudsk JE, Schmidt B, Mazzone P, Fischer S, Lund J, et al. Gender difference in left atrial appendage occlusion outcomes: Results from the AmplatzerTM AmuletTM Observational Study. Int J Cardiol Heart Vasc [Internet]. 2021 [cited 2026 Feb 2]; 35:100848. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333339/.
- Dalen H, Letnes JM. Rethinking Left Atrial Enlargement. JACC: Cardiovascular Imaging [Internet]. 2022 [cited 2026 Feb 2]; 15(6):998–1000. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X22001632.
- Masuda M, Matsuda Y, Uematsu H, Sugino A, Ooka H, Kudo S, et al. Gender Differences in Atrial Fibrosis and Cardiomyopathy Assessed by Left Atrial Low-Voltage Areas During Catheter Ablation of Atrial Fibrillation. The American Journal of Cardiology [Internet]. 2023 [cited 2026 Feb 2]; 203:37–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002914923005349.
- Ma J, Chen Q, Ma S. Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management. J Cell Mol Med [Internet]. 2021 [cited 2026 Feb 2]; 25(6):2764–75. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957273/.
- Nakashima K, Yamaguchi T, Takahashi Y, Otsubo T, Shichida S, Osako R, et al. Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy. European Heart Journal [Internet]. 2026 [cited 2026 Feb 2]; 47(2):217–31. Available from: https://academic.oup.com/eurheartj/article/47/2/217/8263950.
- Masuda M, Matsuda Y, Uematsu H, Sugino A, Ooka H, Kudo S, et al. Sex differences in atrial myocardial fibrosis and degeneration: evaluation using left atrial low-voltage areas during catheter ablation of atrial fibrillation [Internet]. 2023 [cited 2026 Feb 2]. Available from: http://medrxiv.org/lookup/doi/10.1101/2023.02.20.23286210.

